-
Eiger BioPharmaceuticals Discontinues Ubenimex for PAH Clinical Trial
Eiger Biopharmaceuticals has discontinued development Ubenimex for the treatment of pulmonary arterial hypertension (PAH). Read more here.
What are your thoughts on this news?
Sorry, there were no replies found.
Log in to reply.